​

Rani Therapeutics (RANI) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

RANI Stock Forecast

Rani Therapeutics (RANI) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $15.67, with a high of $28.00 and a low of $9.00. This represents a 1324.55% increase from the last price of $1.10.

- $6 $12 $18 $24 $30 High: $28 Avg: $15.67 Low: $9 Last Closed Price: $1.1

RANI Stock Rating

Rani Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

RANI Price Target Upside V Benchmarks

TypeNameUpside
StockRani Therapeutics1324.55%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$1.10$1.10$1.10
Upside/Downside--809.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2524---6
Mar, 2525---7
Feb, 2525---7
Jan, 2526---8
Dec, 2426---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 24, 2024Annabel SamimyStifel Nicolaus$10.00$4.11143.31%809.09%
Mar 27, 2024Edward NashCanaccord Genuity$9.00$3.18183.02%718.18%
Jun 13, 2022Andreas ArgyridesWedbush$28.00$9.40197.87%2445.45%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024H.C. WainwrightBuyBuyhold
Aug 16, 2024H.C. WainwrightBuyBuyhold
Aug 01, 2024OppenheimerOutperforminitialise
Jun 12, 2024Rodman & RenshawBuyinitialise
May 07, 2024H.C. WainwrightBuyBuyhold
Mar 27, 2024Canaccord GenuityBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.69$-2.66$-1.33$-1.05----
Avg Forecast$-1.58$-1.45$-1.57$-1.23$-1.01$-0.73$-0.33$0.17
High Forecast$-1.58$-1.45$-1.41$-1.19$-0.87$-0.03$-0.26$0.17
Low Forecast$-1.58$-1.45$-1.79$-1.29$-1.08$-1.31$-0.40$0.17
Surprise %70.25%83.45%-15.29%-14.63%----

Revenue Forecast

$0 $12M $24M $36M $48M $60M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.72M-------
Avg Forecast$2.19M$92.86K--$4.38M$10.87M$21.78M$55.77M
High Forecast$2.19M$92.86K--$4.38M$10.87M$21.78M$55.77M
Low Forecast$2.19M$92.86K--$4.38M$10.87M$21.78M$55.77M
Surprise %23.96%-------

Net Income Forecast

$-65M $-51M $-37M $-23M $-9M $5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-53.09M$-63.34M$-33.97M$-30.02M----
Avg Forecast$-40.17M$-37.00M$-40.83M$-31.55M$-24.90M$-27.57M$-8.39M$4.23M
High Forecast$-40.17M$-37.00M$-36.07M$-30.32M$-22.30M$-655.70K$-6.65M$4.23M
Low Forecast$-40.17M$-37.00M$-45.59M$-32.79M$-27.50M$-33.42M$-10.13M$4.23M
Surprise %32.16%71.20%-16.81%-4.86%----

RANI Forecast FAQ

Is Rani Therapeutics stock a buy?

Rani Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rani Therapeutics is a favorable investment for most analysts.

What is Rani Therapeutics's price target?

Rani Therapeutics's price target, set by 5 Wall Street analysts, averages $15.67 over the next 12 months. The price target range spans from $9 at the low end to $28 at the high end, suggesting a potential 1324.55% change from the previous closing price of $1.1.

How does Rani Therapeutics stock forecast compare to its benchmarks?

Rani Therapeutics's stock forecast shows a 1324.55% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Rani Therapeutics over the past three months?

  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Rani Therapeutics’s EPS forecast?

Rani Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.01, marking a -3.81% decrease from the reported $-1.05 in 2024. Estimates for the following years are $-0.73 in 2026, $-0.33 in 2027, and $0.17 in 2028.

What is Rani Therapeutics’s revenue forecast?

Rani Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.38M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $10.87M, followed by $21.78M for 2027, and $55.77M for 2028.

What is Rani Therapeutics’s net income forecast?

Rani Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-24.901M, representing a -17.05% decrease from the reported $-30.018M in 2024. Projections indicate $-27.571M in 2026, $-8.392M in 2027, and $4.23M in 2028.